Stocks making the biggest moves premarket: Delta, Tesla, Moderna and others

Deutschland Nachrichten Nachrichten

Stocks making the biggest moves premarket: Delta, Tesla, Moderna and others
Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen
  • 📰 CNBC
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 72%

These are the stocks posting the largest moves before the bell.

– Paccar gained 1.6% in the premarket after the truck maker's stock was upgraded to overweight from equal-weight at Morgan Stanley, which also raised its price target to $136 per share from $91. The firm said Paccar is among the industrial stocks poised to benefit from a sector recovery.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

CNBC /  🏆 12. in US

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Stocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and moreStocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and moreThe stocks making the biggest moves in premarket trading include Oracle, Boeing, Moderna, and more.
Weiterlesen »

Moderna and Merck team-up to fight melanomaModerna and Merck team-up to fight melanomaVaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
Weiterlesen »

Merck, Moderna share positive progress of potential skin cancer vaccineMerck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Weiterlesen »

Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Weiterlesen »

Merck, Moderna detail potential skin cancer vaccine progressMerck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Weiterlesen »



Render Time: 2025-02-27 03:33:01